Consensus Biogen Inc.

Equities

BIIB

US09062X1037

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
215.6 USD -0.33% Intraday chart for Biogen Inc. -2.32% -16.67%

Evolution of the average Target Price on Biogen Inc.

Price target over the last 5 years

History of analyst recommendation changes

9.II9blhJacjPAsB7iK_Su6yCcdigQEFOYNKNSHbjB93s.bfYX13Y2RH24hlGtH43njGz0PBlcXiTVfddkVtSDpxdp-WrwUzBHXvD9Kg~29a1217ee4f88cb9057f8f7f767d6fd1
BIOGEN : Jefferies confirms its Buy rating on the stock CF
Canaccord Genuity Adjusts Price Target on Biogen to $305 From $310, Keeps Buy Rating MT
UBS Cuts Biogen Price Target to $250 From $276, Maintains Neutral Rating MT
Oppenheimer Adjusts Biogen Price Target to $290 From $295, Maintains Outperform Rating MT
The market faces a choice Our Logo
Baird Adjusts Biogen Price Target to $316 From $333, Maintains Outperform Rating MT
Needham Adjusts Biogen Price Target to $300 From $305, Maintains Buy Rating MT
Stifel Adjusts Biogen Price Target to $275 From $287 Maintains Buy Rating MT
Scotiabank Adjusts Biogen Price Target to $275 From $304, Maintains Sector Outperform Rating MT
Piper Sandler Adjusts Biogen Price Target to $325 From $350, Maintains Overweight Rating MT
TD Cowen Adjusts Biogen Price Target to $300 From $305, Maintains Outperform Rating MT
RBC Cuts Price Target on Biogen to $364 From $379 Amid Q4 Miss, Keeps Outperform Rating MT
Wells Fargo Downgrades Biogen to Equalweight From Overweight, Adjusts Price Target to $240 From $315 MT
ANALYST RECOMMENDATIONS : Biogen, Gsk, Hp Inc, Palantir, Walt Disney... Our Logo
US Equity Indexes Slump as Hotter-Than-Expected Inflation Pushes Likelihood of Fed Rate Back MT
Wall St to open lower as hot inflation data stokes rate-cut uncertainty RE
Wait... Not so fast! Our Logo
Wedbush Raises Biogen's Price Target to $245 From $239, Maintains Neutral Rating MT
BofA Securities Cuts Biogen Price Target to $280 From $290, Maintains Neutral Rating MT
UBS Downgrades Biogen to Neutral From Buy, Cuts Price Target to $276 From $311 MT
Nvidia comes to Wall Street's rescue Our Logo
RBC Boosts Price Target on Biogen to $379 From $363, Keeps Outperform Rating MT
Oppenheimer Raises Biogen Price Target to $295 From $280, Maintains Outperform Rating MT
Stifel Cuts Price Target on Biogen to $287 From $315, Maintains Buy Rating MT
Morgan Stanley Cuts Price Target on Biogen to $364 From $373, Keeps Overweight Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
215.6 USD
Average target price
299.6 USD
Spread / Average Target
+38.95%
High Price Target
400 USD
Spread / Highest target
+85.50%
Low Price Target
230 USD
Spread / Lowest Target
+6.66%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Biogen Inc.

Canaccord Genuity
UBS
Oppenheimer
Needham & Co.
Wells Fargo Securities
RBC Capital Markets
Baird
Scotiabank
Stifel Nicolaus
TD Cowen
Piper Sandler
Wedbush
BofA Securities
Morgan Stanley
Raymond James
HSBC
Mizuho Securities
BMO Capital
Barclays
Atlantic Equities
Goldman Sachs
Guggenheim
Argus
Jefferies & Co.
Truist Securities
HC Wainwright
SVB Securities LLC
Cowen
JPMorgan Chase
SVB Leerink
Cantor Fitzgerald
Bernstein
William Blair & Co.
Citigroup
Credit Suisse
DZ Bank
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings